ArticleJournal of anesthesia and translational medicine2024
The impact of esketamine combined with butorphanol on postoperative analgesia and maternal psychological status after cesarean section: A randomized controlled study.
Article in Journal of anesthesia and translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of esketamine intravenous analgesic pump on pain and depression post-cesarean.BMC surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cesarean delivery is a highly invasive procedure that causes moderate to severe pain. Persistent postoperative pain affects the parturients' rapid postoperative recovery. Therefore, we aim to investigate the efficacy and safety of esketamine in postoperative analgesia after cesarean section. Methods: This clinical study, conducted from January 2022 to August 2022, was randomized, controlled, double-blind and approved by the Ethics Committee of Shiyan Renmin Hospital. Group S received intraoperative esketaimine infusion with 0.15 mg/kg/h and postoperative 0.2 mg/kg butorphanol + 2 mg/kg esketaimine for patient-controlled intravenous analgesia (PCIA). Group C received the same volume of 5 % glucose infusion and postoperative butorphanol 0.2 mg/kg for PCIA. The primary outcome was postoperative analgesic effectiveness as reflected by the number of analgesic pumps pressed during 24 h postoperative period by patients. The secondary outcomes included the VAS scores of postoperative pain, Edinburgh Postnatal Depression Scale (EPDS) scores, neonatal Apgar scores, the time to first ambulation, the gut functional recovery time, the rescue analgesic treatments, and adverse effects. Results: A total of 160 parturients participated in the study, and ultimately, 155 patients were included in the final analysis. There was no statistically significant difference in the number of PCA presses between group C [12 (6-18)] and group S [10 (5-22.25)] during 24 h after surgery [P = 0.98, 95 % CI (-3-3)]. The differences in VAS scores between the two groups were not statistically significant at 8 h [P = 0.07, 95 % CI (0-1)], 24 h [P = 0.06, 95 % CI (0-1)], and 96 h [P = 0.09, 95 % CI (0-0)] postoperatively. The EPDS scores of Group S at postoperative 8 h, 24 h, 96 h, and one week were lower than those of the group C (P < 0.001). The incidence of dizziness was higher in Group S [P < 0.05, RR = 0.270, 95 % CI (0.09-0.78)]. Conclusions: The Supplementation of esketamine during the perioperative period does not improve postoperative analgesia after a cesarean section. But esketamine may improve maternal emotional state up to one week after surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.